Aclaris TherapeuticsACRS
ACRS
About: Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
Employees: 64
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
92% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 12
69% more call options, than puts
Call options by funds: $83K | Put options by funds: $49K
44% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 27
11% more funds holding
Funds holding: 97 [Q4 2024] → 108 (+11) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 2 (+0) [Q1 2025]
34% less capital invested
Capital invested by funds: $217M [Q4 2024] → $144M (-$73.3M) [Q1 2025]
36.6% less ownership
Funds ownership: 122.49% [Q4 2024] → 85.89% (-36.6%) [Q1 2025]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$8
444%
upside
Avg. target
$11
648%
upside
High target
$16
988%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Wedbush Martin Fan | 444%upside $8 | Outperform Initiated | 28 May 2025 |
HC Wainwright & Co. Raghuram Selvaraju | 988%upside $16 | Buy Maintained | 14 May 2025 |
Scotiabank Louise Chen | 512%upside $9 | Sector Outperform Maintained | 9 May 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
2 weeks ago
Aclaris Therapeutics to Participate in Two June Healthcare Conferences
WAYNE, Pa., May 28, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company will participate in two upcoming healthcare conferences in June.
Neutral
GlobeNewsWire
1 month ago
Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series
WAYNE, Pa., May 09, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that Aclaris' Chief Executive Officer Neal Walker and other members of the Aclaris senior leadership team will participate in a fireside chat during the virtual HC Wainwright “HCW@Home” series. The virtual fireside chat will take place on Friday May 16, 2025, at 1:00 PM EDT.
Negative
Zacks Investment Research
1 month ago
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Misses Revenue Estimates
Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.24 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
- Multiple Catalysts in Immuno-Inflammatory Indications Anticipated in 2025 and 2026 - - Expected Cash Runway Extended Through the First Half of 2028 - - Phase 2 Results Received to Date from Chinese Partner CTTQ Provide Clinical Evidence of Enhanced Potency of Bosakitug (ATI-045) and Opportunity for Development Partnerships - - Investigational New Drug (IND) Application for Bispecific Antibody ATI-052 Cleared by U.S. Food and Drug Administration - WAYNE, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the first quarter of 2025 and provided a corporate update.
Neutral
GlobeNewsWire
1 month ago
Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer
WAYNE, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that Jesse Hall, M.D. has been appointed as Chief Medical Officer.
Neutral
GlobeNewsWire
3 months ago
Aclaris Therapeutics to Participate in Two March Healthcare Conferences
WAYNE, Pa., March 04, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company will participate in two upcoming healthcare conferences in March. On Tuesday March 11, 2025, at 3:00 PM EDT, Aclaris' Chief Executive Officer Dr. Neal Walker and other members of Aclaris' senior leadership team will participate in a fireside chat during the Leerink Partners Global Healthcare Conference in Miami, Florida.
Negative
Zacks Investment Research
3 months ago
Aclaris Therapeutics (ACRS) Reports Q4 Loss, Tops Revenue Estimates
Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.30 per share a year ago.
Neutral
GlobeNewsWire
4 months ago
New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3
- Data Generated to Date Support Potential for Aclaris' ATI-2138 to Impact Several Human Inflammatory Diseases - WAYNE, Pa., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced the availability of a new publication describing the unique properties of Aclaris Therapeutics' ATI-2138, a novel investigational covalent inhibitor of interleukin-2-inducible T cell kinase (ITK) and Janus kinase 3 (JAK3) in development for the treatment of autoimmune and inflammatory diseases.
Neutral
GlobeNewsWire
4 months ago
Aclaris Therapeutics Announces Formation of New Scientific Advisory Board
WAYNE, Pa., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced the formation of a new Scientific Advisory Board (SAB), which initially includes experts in the field of pulmonology. These include Marianne Mann, M.D.
Neutral
GlobeNewsWire
5 months ago
Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WAYNE, Pa., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS) (the “Company” or “Aclaris”), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that effective January 2, 2025, the Compensation Committee of Aclaris' Board of Directors (the Committee) granted nonstatutory stock options to purchase an aggregate of 215,000 shares of its common stock and 61,000 restricted stock units to 1 new employee under the Aclaris Therapeutics, Inc. 2024 Inducement Plan (the “2024 Inducement Plan”). The stock options and restricted stock units were granted as inducements material to the new employee becoming an employee of Aclaris in accordance with NASDAQ Listing Rule 5635(c)(4).
Charts implemented using Lightweight Charts™